Sava Medica Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.91 Cr
as on 16-11-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 73.59%
(FY 2023)
- Ebitda 78.29%
(FY 2023)
- Net Worth -0.38%
(FY 2023)
- Total Assets -0.63%
(FY 2023)
About Sava Medica
The Corporate was formerly known as Sava Medica Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.91 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sava Medica Limited India is Nikhil Kulkarni as COMPANY SECRETARY. Suvarna Jadhav, Vishal Jadhav, and Renu Anjanikar serve as directors at the Company.
- CIN/LLPIN
U74999GJ2010PLC118600
- Company No.
135514
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Feb 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surendra Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sava Medica Limited offer?
Sava Medica Limited offers a wide range of products and services, including Water Treatment & Purification Plant, Reverse Osmosis Plant Parts.
Who are the key members and board of directors at Sava Medica?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikhil Kulkarni  | Company Secretary | 12-Feb-2020 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vishal Jadhav | Director | 18-Sep-2012 | Current |
| Renu Anjanikar | Director | 05-Jul-2016 | Current |
| Suvarna Jadhav | Director | 10-Feb-2010 | Current |
Financial Performance and Corporate Structure Insights of Sava Medica.
Sava Medica Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 73.59% increase in profit. The company's net worth dipped by a decrease of 0.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sava Medica?
In 2023, Sava Medica had a promoter holding of 99.41% and a public holding of 0.60%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sava Medica?
Sava Medica has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sava Medica, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sava Medica's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
